Browse > Article
http://dx.doi.org/10.3904/kjm.2013.85.6.598

Reactivation of Hepatitis B Virus Following Systemic Chemotherapy for Malignant Lymphoma  

Jang, Seung Jun (Division of Gastroenterology, Department of Internal Medicine, Gachon University Gil Medical Center)
Jung, Young Kul (Division of Gastroenterology, Department of Internal Medicine, Gachon University Gil Medical Center)
Baek, Hae Lim (Division of Gastroenterology, Department of Internal Medicine, Gachon University Gil Medical Center)
Yoon, Hyun Hwa (Division of Gastroenterology, Department of Internal Medicine, Gachon University Gil Medical Center)
Shin, Seung Kak (Division of Gastroenterology, Department of Internal Medicine, Gachon University Gil Medical Center)
Hong, Jun Shik (Division of Gastroenterology, Department of Internal Medicine, Gachon University Gil Medical Center)
Park, Jin Ny (Division of Gastroenterology, Department of Internal Medicine, Gachon University Gil Medical Center)
Kwon, Oh Sang (Division of Gastroenterology, Department of Internal Medicine, Gachon University Gil Medical Center)
Kim, Yun Soo (Division of Gastroenterology, Department of Internal Medicine, Gachon University Gil Medical Center)
Choi, Duck Joo (Division of Gastroenterology, Department of Internal Medicine, Gachon University Gil Medical Center)
Lee, Jae Hoon (Division of Gastroenterology, Department of Internal Medicine, Gachon University Gil Medical Center)
Kim, Ju Hyun (Division of Gastroenterology, Department of Internal Medicine, Gachon University Gil Medical Center)
Publication Information
The Korean Journal of Medicine / v.85, no.6, 2013 , pp. 598-603 More about this Journal
Abstract
Background/Aims: Reactivation of hepatitis B virus (HBV) has been reported in HBV surface antigen (HBsAg)-positive patients undergoing chemotherapy, as well as HBsAg-negative patients with antibodies against HBV core antigen (HBcAg) and/or HBsAg (HBsAb). Chemotherapy-including rituximab-has recently been identified as a predictive factor for HBV reactivation in HBsAg-negative patients with malignant lymphoma. The aim of our study was to identify the factors predictive of HBV reactivation after chemotherapy in patients with malignant lymphoma. Methods: We conducted a retrospective analysis of medical records from patients diagnosed with malignant lymphoma at Gachon University Gil Medical Center in City, County from January 2005 to December 2010. We subsequently determined HBsAg, HBsAb and anti-HBc status in the 196 patients treated with chemotherapy. Results: The mean age of the patients was 57.3 ${\pm}$ 14.5 years; 56.3% were male. A total of 172 of 196 (88%) patients in the study population were HBsAg (+) prior to chemotherapy. Three patients (3/11, 27.3%) in the HBsAg (+) group had confirmed HBV reactivation after chemotherapy. In addition, 26 of 196 (13%) patients in the study population tested HBcAg (+) positive prior to chemotherapy. One patient (1/15, 6.7%) in the HBsAg (-)/HBcAb (+) group had confirmed HBV reactivation. In the four patients with HBV reactivation, infection was resolved after treatment with 0.5 mg entecavir or 100 mg lamivudine. Conclusions: Reactivation of HBV after systemic chemotherapy can occur in HBsAg (-) patients. We recommend that malignant lymphoma patients undergoing chemotherapy be screened for HBV infection status, including HBcAg, and followed closely to prevent HBV reactivation.
Keywords
Hepatitis B; Hepatitis B Core Antigen; Chemotherapy; Lymphoma;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Niitsu N, Hagiwara Y, Tanae K, Kohri M, Takahashi N. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy. J Clin Oncol 2010;28:5097-5100.   DOI   ScienceOn
2 Matsue K, Kimura S, Takanashi Y, et al. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer 2010;116: 4769-4776.   DOI   ScienceOn
3 Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 2009;90:13-23.   DOI
4 Kim EB, Kim DS, Park SJ, Park Y, Rho KH, Kim SJ. Hepatitis B virus reactivation in a surface antigen-negative and antibody-positive patient after rituximab plus CHOP chemotherapy. Cancer Res Treat 2008;40:36-38.   DOI   ScienceOn
5 Zurawska U, Hicks LK, Woo G, et al. Hepatitis B virus screening before chemotherapy for lymphoma: a costeffectiveness analysis. J Clin Oncol 2012;30:3167-3173.   DOI
6 Ohishi W, Chayama K. Prevention of hepatitis B virus reactivation in immunosuppressive therapy or chemotherapy. Clin Exp Nephrol 2011;15:634-640.   DOI   ScienceOn
7 Jang JW. Management of patients with hepatitis B virus infection who receive immunosuppressive treatment or chemotherapy. Korean J Med 2012;82:149-158.   DOI
8 Tsutsumi Y, Ogasawara R, Kamihara Y, et al. Rituximab administration and reactivation of HBV. Hepat Res Treat 2010;2010:182067.
9 Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125:1742-1749.   DOI   ScienceOn
10 Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009;27:605-611.   DOI
11 Kwang JY, Jung SH, Kang YK, et al. Acute excerbation of hepatitis in hepatitis B virus carriers with non-Hodgkin's lymphoma after chemotherapy. Korean J Gastroenterol 2000;35:64-72.
12 Hui CK, Cheung WW, Au WY, et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 2005;54:1597-1603.   DOI   ScienceOn
13 Pei SN, Ma MC, Wang MC, et al. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy. Ann Hematol 2012;91:1007-1012.   DOI   ScienceOn
14 Chung SM, Sohn JH, Kim TY, et al. Fulminant hepatic failure with hepatitis B virus reactivation after rituximab treatment in a patient with resolved hepatitis B. Korean J Gastroenterol 2010;55:266-269.   DOI   ScienceOn
15 Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008;148:519-528.   DOI   ScienceOn
16 Oketani M, Ido A, Uto H, Tsubouchi H. Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. Hepatol Res 2012;42: 627-636.   DOI   ScienceOn
17 Kusumoto S, Tanaka Y, Ueda R, Mizokami M. Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy. J Gastroenterol 2011;46:9-16.   DOI